Acadia’s schizophrenia drug trial fails to meet primary endpoint

US-based biopharmaceutical company Acadia Pharmaceuticals has reported that its Phase III ADVANCE-2 clinical trial of pimavanserin for the treatment of negative symptoms of schizophrenia did not meet its primary endpoint.